{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:25:13Z","timestamp":1794086713164,"version":"4.8.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,17]],"date-time":"2027-09-17T00:00:00Z","timestamp":1821139200000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI116635"],"award-info":[{"award-number":["R01-AI116635"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.antiviral.2026.106536","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:34:11Z","timestamp":1789572851000},"page":"106536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials"],"prefix":"10.1016","volume":"255","author":[{"given":"Sunwen","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Minyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6826-1633","authenticated-orcid":false,"given":"Justin","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2026.106536_bib1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106536_bib2","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.00986-15","article-title":"Antagonistic relationship between human cytomegalovirus pUL27 and pUL97 activities during infection","volume":"89","author":"Bigley","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106536_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/AAC.01177-08","article-title":"Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir","volume":"53","author":"Chou","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106536_bib4","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.00186-10","article-title":"Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106536_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106536_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients","volume":"229","author":"Chou","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106536_bib7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/infdis\/jit654","article-title":"Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial","volume":"209","author":"Chou","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106536_bib8","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1128\/JCM.00391-17","article-title":"Differentiated levels of ganciclovir resistance conferred by mutations at codons 591 to 603 of the cytomegalovirus UL97 kinase gene","volume":"55","author":"Chou","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2026.106536_bib9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106536_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106340","article-title":"A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials","volume":"246","author":"Chou","year":"2026","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106536_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105792","article-title":"Ganciclovir and maribavir cross-resistance revisited: relative drug susceptibilities of canonical cytomegalovirus mutants","volume":"222","author":"Chou","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106536_bib12","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1093\/infdis\/jiae469","article-title":"Comparative emergence of maribavir and ganciclovir resistance in a randomized Phase 3 clinical trial for treatment of cytomegalovirus infection","volume":"231","author":"Chou","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106536_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104616","article-title":"UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","volume":"172","author":"Chou","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106536_bib14","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1128\/JVI.72.7.5927-5936.1998","article-title":"Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments","volume":"72","author":"Cihlar","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106536_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0166-3542(98)00051-5","article-title":"Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant","volume":"40","author":"Faizi Khan","year":"1998","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106536_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105623","article-title":"Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients","volume":"215","author":"Kleiboeker","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106536_bib17","doi-asserted-by":"crossref","first-page":"11499","DOI":"10.1128\/JVI.77.21.11499-11506.2003","article-title":"Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27","volume":"77","author":"Komazin","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106536_bib18","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The Fourth International Consensus Guidelines on the management of Cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2026.106536_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00829-23","article-title":"Development and validation of a next-generation sequencing assay with open-access analysis software for detecting resistance-associated mutations in CMV","volume":"61","author":"Mallory","year":"2023","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2026.106536_bib20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106536_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.106016","article-title":"Comprehensive herpesviruses antiviral drug resistance mutation database (CHARMD)","author":"Tilloy","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106536_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02425-18","article-title":"Patient-derived cytomegaloviruses with different ganciclovir sensitivities from UL97 mutation retain their replication efficiency and some kinase activity in vitro","volume":"63","author":"Wong","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226001956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226001956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:22:18Z","timestamp":1794086538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354226001956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"alternative-id":["S0166354226001956"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106536","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106536"}}